잠시만 기다려 주세요. 로딩중입니다.

Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party

대한혈액학회지 2016년 51권 3호 p.193 ~ 199
김석진 ( Kim Seok-Jin ) - Sungkyunkwan University School of Medicine Samsung Medical Center Department of Medicine

방수미 ( Bang Soo-Mee ) - Seoul National University Bundang Hospital Department of Internal Medicine
최윤석 ( Choi Yoon-Seok ) - Chungnam National University School of Medicine Department of Internal Medicine
조덕연 ( Jo Deog-Yeon ) - Chungnam National University School of Medicine Department of Internal Medicine
김진석 ( Kim Jin-Seok ) - Yonsei University College of Medicine Severance Hospital Department of Internal Medicine
이혜원 ( Lee Hye-Won ) - National Cancer Center Hematology-Oncology Clinic
엄현석 ( Eom Hyeon-Seok ) - National Cancer Center Hematology-Oncology Clinic
윤덕현 ( Yoon Dok-Hyun ) - University of Ulsan College of Medicine Asan Medical Center Department of Oncology
서철원 ( Suh Cheol-Won ) - University of Ulsan College of Medicine Asan Medical Center Department of Oncology
이제중 ( Lee Je-Jung ) - Chonnam National University Hwasun Hospital Department of Hematology-Oncology
홍준식 ( Hong Jun-Shik ) - Gachon University School of Medicine Department of Internal Medicine
이재훈 ( Lee Jae-Hoon ) - Gachon University School of Medicine Department of Internal Medicine
고영일 ( Koh Young-Il ) - Seoul National University College of Medicine Department of Internal Medicine
김기현 ( Kim Ki-Hyun ) - Sungkyunkwan University School of Medicine Samsung Medical Center Department of Medicine
윤성수 ( Yoon Sung-Soo ) - Seoul National University College of Medicine Department of Internal Medicine
민창기 ( Min Chang-Ki ) - Catholic University College of Medicine Seoul St. Mary’s Hospital Department of Internal Medicine

Abstract


Background: Bendamustine may be a potential treatment option for patients with myeloma, but little is known about the utility of bendamustine as a salvage treatment, especially in Asian patients.

Methods: We performed a multicenter retrospective study of patients with relapsed or refractory myeloma who received bendamustine and prednisone.

Results: The records of 65 heavily pre-treated patients, who had undergone bortezomib and lenalidomide treatment (median number of previous treatments: 5), were analyzed. The median time from diagnosis to bendamustine treatment was 3.8 years, and the median patient age was 63 years (range, 38?77 yr). The responses to the last treatment before bendamustine were refractory disease (N=52, 80%) or disease progression from partial response (N=13, 20%). Twenty-three patients responded to the treatment, with an overall response rate of 35% (23/65), and the median number of bendamustine treatment cycles was two (range, 1?5 cycles). The median overall survival after bendamustine treatment was 5.5 months and the overall survival rate in responders to bendamustine was significantly better than that in non-responders (P=0.036).

Conclusion: Bendamustine may be a potential salvage treatment to extend survival in a select group of heavily pre-treated patients with relapsed or refractory myeloma.

키워드

Myeloma; Bendamustine; Response; Toxicity; Survival
원문 및 링크아웃 정보
  
등재저널 정보